New findings suggest investigational therapy may overcome a longstanding challenge in treating primary CoQ10 deficiency.
In drug development, sometimes, the biggest story is what regulators are willing to do with the evidence.
AI-powered, clinical-stage biopharma company BPGbio has revealed new findings supporting BPM31510, its investigational therapy for primary CoQ10 deficiency (PCQD), while revealing something equally notable: following a Type C meeting with the US Food and Drug Administration (FDA), the company is preparing to move into a pivotal Phase 3 trial [1].
Look closer, three bigger questions emerge:
Firstly, is the FDA beginning to rethink how it evaluates treatments for devastating ultra-rare diseases, where traditional large clinical trials are often impossible? BPGbio’s case rests on a combination of translational science and compassionate-use experience in just four pediatric patients, a remarkably small clinical dataset by conventional standards.
Secondly, could the therapy have solved one of mitochondrial medicine’s most stubborn engineering problems: delivering CoQ10 into the organs that need it most, particularly the brain?
Finally, does this fit into something much larger? Across biotech, 2026 is increasingly looking like the year mitochondria stepped out of the shadows. Rather than editing genes or replacing cells, companies are asking a simpler question: what if we could restore the cell’s power supply instead?
These questions reach well beyond one rare disease; they touch on how we think about aging itself.
When supplements simply aren’t enough
CoQ10 has become almost synonymous with healthy aging. Millions of people take it hoping to support energy, heart health or mitochondrial function. However, for children born with primary CoQ10 deficiency, the problem isn’t a lack of supplements; it’s that their bodies cannot properly produce or distribute the molecule in the first place.
Think of CoQ10 as fuel for the tiny power stations inside every cell: the mitochondria. Without enough fuel, those power stations begin shutting down. The organs that consume the most energy – the brain, muscles and kidneys – are usually the first to suffer.
That is why PCQD causes progressive neurological decline, muscle weakness and kidney disease. It is also why oral CoQ10 has produced inconsistent results. Taking more of the molecule doesn’t necessarily mean it reaches the places where it is needed, much like pouring extra water into a city’s reservoir doesn’t guarantee every neighborhood receives it if the pipes are blocked.
BPGbio’s investigational therapy, BPM31510, attempts to solve the delivery problem rather than simply increasing supply.
More than encouraging clinical observations
At the 2026 United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine Conference, BPGbio presented clinical findings from four children with genetically confirmed PCQD who received BPM31510 through compassionate use after oral CoQ10 had provided little or only temporary benefit.
Across all four patients, the therapy was generally well tolerated, with no drug-related clinically significant adverse events reported.
Researchers also observed improvements in walking, balance and coordination, alongside reported gains in muscle strength, reduced fatigue and better day-to-day functioning. Some improvements appeared within four weeks of treatment.
Four patients would hardly constitute convincing evidence for a common disease. However, PCQD is anything but common. In ultra-rare disorders, every carefully documented patient can contribute meaningful evidence, particularly when clinical findings are reinforced by biological data that explain why the therapy may be working. That combination is what makes this story noteworthy.
Reaching the places that matter
Alongside the clinical data, BPGbio presented translational findings from animal models showing that BPM31510 increased the CoQ pool in the brain and kidneys – two organs heavily affected by PCQD.
For researchers, this may be the more important result. One of medicine’s greatest challenges is not discovering therapeutic molecules, but delivering them. The brain, protected by the highly selective blood-brain barrier, has frustrated drug developers for decades. Many promising compounds simply cannot get through.
BPGbio is not claiming to have broadly solved drug delivery to the brain, and these findings remain preclinical, but demonstrating that CoQ10 successfully reached brain tissue in disease models strengthens the biological rationale behind the clinical observations. It suggests the therapy is doing something conventional supplementation has struggled to achieve: delivering the molecule where it can actually support cellular energy production.
“The totality of evidence generated to date – spanning compassionate use experience, translational science and regulatory engagement – provides an encouraging foundation for continued development of BPM31510 in PCQD,” said Frank J Sasinowski, MS, MPH, JD, Director at Hyman, Phelps & McNamara, PC and regulatory counsel to BPGbio.
“The emerging body of evidence supporting BPM31510, coupled with constructive FDA engagement, reflects a thoughtful and rigorous approach toward advancing a potential therapy for patients facing a serious unmet medical need,” he added.
The FDA may be evolving, too
Perhaps the most consequential development is what happened outside the laboratory. Following discussions with the FDA earlier this year, BPGbio says it has aligned with the agency on a path toward a Phase 3 pivotal trial. That does not mean regulatory standards are being lowered. Rather, it reflects a growing recognition that rare diseases cannot always be evaluated through the same framework used for conditions affecting millions of patients.
When patient populations are exceptionally small and diseases relentlessly progressive, regulators increasingly look at the totality of evidence – clinical outcomes, translational science and mechanistic understanding together.
If that trend continues, it could accelerate development for therapies targeting other ultra-rare disorders where traditional trial designs are simply unrealistic.
“Primary CoQ10 deficiency is a devastating mitochondrial disorder with profound unmet need, particularly for pediatric patients facing progressive neurological decline,” said Dr Niven R Narain, president and CEO of BPGbio. “As we advance preparations for a planned Phase 3 pivotal trial following constructive discussions with the FDA this spring, we remain focused on bringing a potential new therapeutic option to patients and families affected by this severe mitochondrial disease.”
Whether BPM31510 ultimately succeeds will depend on larger clinical trials. That remains the critical test. Yet its story shows how companies are treating mitochondria not as a downstream consequence of aging, but as a therapeutic target in their own right. From rare pediatric disorders to metabolic disease, the field is shifting toward understanding how to restore the machinery already inside our cells.
Now, if the FDA is becoming more willing to evaluate promising therapies through the lens of the totality of evidence, it could reshape innovation for patients with the rarest diseases. If therapies like BPM31510 can reliably deliver CoQ10 into organs such as the brain, they may overcome one of mitochondrial medicine’s longest-standing technical barriers.
Finally, if 2026 truly marks the emergence of a “mitochondrial reset” era, then BPGbio’s announcement may represent more than progress for one ultra-rare condition – it could be another sign that longevity science is entering a phase focused less on changing our genes and more on restoring the engines that keep every cell alive.
